Tabata Atsushi, Ohkubo Yukimasa, Anyoji Natsuki, Hojo Keiko, Tomoyasu Toshifumi, Tatematsu Youhei, Ohkura Kazuto, Nagamune Hideaki
Department of Biological Science and Technology, Life System, Institute of Technology and Science, Tokushima University Graduate School, Tokushima, Japan.
Faculty of Pharmaceutical Sciences and Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe, Japan.
Anticancer Res. 2015 Aug;35(8):4411-7.
BACKGROUND/AIM: In order to develop an efficient drug-delivery system (DDS), a lipopeptide-loaded liposome that functions as a platform for the transpeptidase reaction mediated by sortase A (SrtA) was constructed and its stability, as well as cell-specific targeting were evaluated in the present study.
Several lipopeptides possessing an acceptor peptide sequence (oligoglycine ≥ three residues) or donor peptide sequence (LPETG) for the SrtA-mediated reaction were chemically synthesized and then inserted into the liposome membrane composed of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and cholesterol (DPPC-Chol-lipo) to obtain the lipopeptide-loaded liposomes. The transpeptidase reaction mediated by recombinant SrtA (His-ΔN59SrtA) was employed to modify the peptide moiety on the liposomal surface using a fluorescently-labeled substrate peptide corresponding to the species of each loaded lipopeptide. Furthermore, lung tumor-binding peptide (LTBP)-labeled liposomes, prepared by this transpeptidase reaction, were investigated for selective targeting to lung cancer cells in vitro.
The His-ΔN59SrtA-mediated transpeptidation of fluorescently-labeled peptide on the lipopeptide-loaded DPPC-Chol-lipo was confirmed. The selective targeting of LTBP-labeled liposomes to the lung cancer cell line A549 was also observed in vitro. These results suggest that the labeling of acceptor or donor lipopeptide-loaded liposomes with the transpeptidase SrtA could be a useful method for developing a platform applicable to a cancer-targeting DDS.
背景/目的:为了开发一种高效的药物递送系统(DDS),构建了一种负载脂肽的脂质体,其作为分选酶A(SrtA)介导的转肽酶反应的平台,并在本研究中评估了其稳定性以及细胞特异性靶向性。
化学合成了几种具有用于SrtA介导反应的受体肽序列(寡甘氨酸≥三个残基)或供体肽序列(LPETG)的脂肽,然后将其插入由1,2-二棕榈酰-sn-甘油-3-磷酸胆碱(DPPC)和胆固醇组成的脂质体膜(DPPC-胆固醇脂质体)中,以获得负载脂肽的脂质体。利用重组SrtA(His-ΔN59SrtA)介导的转肽酶反应,使用与每种负载脂肽种类对应的荧光标记底物肽修饰脂质体表面的肽部分。此外,研究了通过这种转肽酶反应制备的肺肿瘤结合肽(LTBP)标记的脂质体在体外对肺癌细胞的选择性靶向作用。
证实了His-ΔN59SrtA介导的负载脂肽的DPPC-胆固醇脂质体上荧光标记肽的转肽作用。在体外也观察到LTBP标记的脂质体对肺癌细胞系A549的选择性靶向作用。这些结果表明,用转肽酶SrtA标记负载受体或供体脂肽的脂质体可能是开发适用于癌症靶向DDS的平台的一种有用方法。